Si deseas distinguir tus productos, servicios o ambos de los de otra empresa, es posible que necesites una marca o nombre comercial. Descubre qué son, en qué consiste su procedimiento de registro y qué implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Si tienes un nuevo dispositivo, producto o procedimiento que resuelva un problema técnico o tenga una ventaja práctica, existen distintas formas de protegerlo en España y en otros países. Descubre cómo hacerlo.
¿Tu innovación reside en la estética, la ornamentación o la apariencia de tu producto? Protégela mediante un diseño industrial. Descubre qué derechos confiere el registro y cómo realizar la tramitación.
Las indicaciones geográficas protegen el nombre de un producto originario de una zona geográfica, a la cual le debe una determinada calidad, reputación u otra característica. Descubre qué son, en qué consiste su procedimiento de registro y qué beneficios conceden.
Las patentes publicadas en todo el mundo son una valiosa fuente de información científica, técnica y comercial.
La Oficina de Propiedad Intelectual de la Unión Europea cierra la solicitud de ayuda del Fondo para pymes (SME Fund) hasta la siguiente convocatoria en 2026.
Si eres emprendedor/a o una empresa y quieres potenciar y mejorar la rentabilidad de tu negocio protegiendo de forma adecuada los activos intangibles de tu organización, en este espacio encontrarás lo necesario.
222
resultados
Última actualización
05/02/2026 [06:51:00]
Resultados 175 a 200 de 222
Resumen de: WO2026017841A1
The present invention provides a homogeneous population of cell-derived nanoparticles, comprising (a) a surface, wherein the surface comprises a.1) a portion of an isolated cellular membrane and a.2) at least one fusion protein comprising RVG peptide fused to lysosome-associated membrane protein 2b, and (b) at least one cargo of interest.
Resumen de: WO2026019628A1
Provided herein are methods and compositions for treating parasitic diseases using nanobubbles in combination with at least one anti-parasitic agent.
Resumen de: WO2026019819A1
Dengue virus (DENV) is a rapidly expanding infectious disease threat that causes an estimated 100 million symptomatic infections every year. A barrier to preventing DENV infections with traditional vaccines or prophylactic monoclonal antibody (mAb) therapies is the phenomenon of Antibody-Dependent Enhancement (ADE). IgG is not the only antibody isotype capable of binding and neutralizing DENV, as DENV-specific IgA1 isotype mAbs can bind and neutralize DENV while without exhibiting any ADE activity. Here we describe the development and optimization of a DENV-specific single-chain IgA construct that retains the desirable biological properties of the parental IgA mAb yet is compatible with efficient in vivo delivery with a novel/liver-tropic lipid nanoparticle. We propose that this platform is uniquely and exceptionally well suited for preventing and/or treating DENV infections and may have broad applicability in the greater infectious disease space in situations where the use of IgG isotype mAbs may be counter indicated.
Resumen de: WO2026019401A1
The present invention relates to a nanosuspension composition comprising a) Canagliflozin or its pharmaceutically acceptable salts, b) hydroxypropyl methylcellulose, c) sodium lauryl sulphate, and d) at least one more surfactant. The said nanosuspension composition has a desirable pharmacokinetic characteristic and better dissolution properties. The invention further relates to a process for the preparation of said nanosuspension composition and use thereof for the preparation of medicament, which is useful in the treatment of type 2 diabetes mellitus.
Resumen de: WO2026018264A1
The present invention relates to a nanoformulation comprising L-leucyl-L-leucine methyl ester (LLOMe) and a polymer for wound healing, which promotes multiple molecular signaling pathways essential for faster wound healing. The nanoformulation offers faster and improved wound and tissue healing, axon regeneration, antiviral immunity, stem cell proliferation, embryonic development, and anti-aging effects.
Resumen de: WO2026016710A1
Disclosed are a substance represented by general formula (I), a substance represented by general formula (II), and a substance represented by general formula (III) for degrading a protein of interest (POI) in a ubiquitin-proteasome system (UPS): PEG-Ra general formula (I) PEG-Rb general formula (II) (Ra-PEG)m-PAMAM-(PEG-Rb)n general formula (III), wherein Ra, Rb, m, and n are as defined in the present disclosure.
Resumen de: WO2026016711A1
The present invention relates to a substance represented by general formula (I) and a substance represented by general formula (II) for degrading a protein of interest (POI) in a ubiquitin-proteasome system (UPS): PLA-PEG-Ra general formula (I) PLA-PEG-Rb general formula (II), wherein Ra and Rb are as defined in the present invention.
Resumen de: WO2026016457A1
Theranostic targeted ultrasonic blasting nano-bubbles, a preparation method therefor, and use thereof, wherein the nano-bubbles are the targeted drug-gene nano-bubbles miRNA/FTY720/PFP@PEI-T7 NBs. The nano-bubbles can be used for preparing a thyroid ultrasound diagnostic agent or a drug for treating thyroid cancer.
Resumen de: AU2025283586A1
Abstract Provided herein are engineered nucleic acids (e.g., expression vectors, including viral vectors, such as lentiviral vectors, adenoviral vectors, AAV vectors, herpes viral vectors, and retroviral vectors) that encode OCT4; KLF4; SOX2 (or any combination thereof) that are useful, for example, in inducing cellular reprogramming, tissue repair, tissue regeneration, organ regeneration, reversing aging (or any combination thereof). Also provided herein are recombinant viruses (e.g., lentiviruses, alphaviruses, vaccinia viruses, adenoviruses, herpes viruses, retroviruses, or AAVs) comprising the engineered nucleic acids (e.g., engineered nucleic acids), engineered cells, compositions comprising the engineered nucleic acids, the recombinant viruses, engineered cells, engineered proteins, chemical agents that are capable of activating expression of OCT4; KLF4; SOX2 (or any combination thereof), an engineered protein selected from the group consisting of OCT4; KLF4; SOX2 (or any combination thereof), an antibody capable of activating expression of OCT4; KLF4; SOX2 (or any combination thereof), methods of treating a disease (e.g., ocular disease) or preventing a disease (e.g., ocular disease), and methods of regulating (e.g., inducing or inducing and then stopping) cellular reprogramming, tissue repair, tissue regeneration (or any combination thereof).
Resumen de: AU2024312860A1
The present disclosure describes improved LNP-based RNA vaccines, nucleobase editing systems, and therapeutics for use in treating and/or immunization against disease. In particular, the disclosure describes improved LNPs, including novel and improved ionizable lipids for making LNPs, that enhance the targeted delivery of LNP-based RNA vaccines and therapeutics based on linear and/or circular mRNAs. The improved LNPs protect linear and/or circular mRNA payloads from degradation and clearance while achieving targeted systemic or local delivery for use as enhanced vaccines and/or therapeutic agents.
Resumen de: AU2024314758A1
The present invention relates to compositions comprising sHDL nanoparticles. In particular, the present invention relates to sHDL nanoparticles comprising a phospholipid; an apoplipoprotein mimetic; a thiol-reactive lipid; and a peptide comprising a linker moiety connected with a payload moiety, wherein the linker comprises cysteine (C) and one to five amino acids independently selected from aspartic acid (D), glutamic acid (E), and serine (S), the payload comprises a polypeptide that is 5 to 35 amino acids in length and has a net positive charge at a pH of 7 to 12, and the peptide comprises a net negative charge at a pH of 7 and an isoelectric point of 0.4 to 12; and wherein the peptide is covalently attached to the thiol-reactive lipid by way of the cysteine (C).
Resumen de: AU2024309710A1
Described is a method for the preparation of an aqueous mesoparticle composition comprising a lipophilic compound, comprising the steps of: a. Providing an emulsifier or a blend of emulsifiers in powder form; b. Mixing one or more oils at a temperature above 40°C where all oils have become liquid, wherein said oils differ in melting temperature and which mixture comprises at least a sufficient amount of medium chain triglycerides to enable the composition formed in step g have a partly liquid oil phase at temperatures around about 4°C; c. Adding the hydrophobic or amphiphilic compound in any hydrophobic solvent to the oil mixture; d. Optionally letting the mixture cool down to room temperature; e. Adding the emulsifier powder and water to the oil mixture and letting the mixture emulsify, under optional agitation and heating to 30-40°C; f. Subjecting the emulsified mixture to a sonication and optionally mixing or fluidisation treatment until the average particle size of the mixture remains stable; g. Cooling down the sonicated mixture allowing sufficient time for crystallisation; and h. Optionally, a second sonication treatment while keeping the mixture cold and compositions produced by the above method.
Resumen de: AU2024307443A1
The present invention provides an ionizable lipid and a drug delivery system comprising the ionizable lipid. Specifically, the present invention provides an ionizable lipid having a structure of formula (I), or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof. Lipid nanoparticles constructed by using the ionizable lipid can realize safe and efficient delivery of nucleic acid drugs, small molecule drugs, peptide drugs and protein drugs.
Resumen de: AU2024303397A1
Provided is a rapidly-metabolized lipid compound. The present invention relates in particular to a compound represented by formula (I), or a pharmaceutically acceptable salt, an isotopic variant, a tautomer or a stereoisomer thereof. Also provided are a nanoparticle pharmaceutical composition comprising the compound, and a use of the compound and a composition thereof in delivering nucleic acids.
Resumen de: AU2024299322A1
Compositions and methods for delivery of therapeutic peptides are disclosed herein. In some embodiments, for example, a composition for treating a disease or condition includes a dynamic hydrogel, and an acylated peptide encapsulated by the dynamic hydrogel. The dynamic hydrogel can include a polymer and a plurality of nanoparticles. The polymer can be non-covalently crosslinked with the plurality of nanoparticles.
Resumen de: AU2024289116A1
The present invention relates to a composition comprising a solid carrier, an engineered phenylalanine ammonia lyase or a fragment thereof immobilized on the surface of the solid carrier, a protective layer to protect the engineered phenylalanine ammonia lyase or a fragment thereof by embedding the engineered phenylalanine ammonia lyase or a fragment thereof, and a functional constituent immobilized on the surface of the protective layer, wherein the functional constituent immobilized on the surface of the protective layer is a polymer comprising repeat units wherein each repeat unit comprises at least one amino group and/or at least one thiol group. The present invention also relates to methods of producing said composition and uses thereof.
Resumen de: AU2024252644A1
Disclosed are a new nanobody (Nb) targeting a tissue factor (TF) and a nanobody-drug conjugate (NDC), a preparation method therefor and the use thereof. The monoclonal nanobody and the corresponding NDC can efficiently and high-specifically bind to a purified TF protein and a TF on the surface of various TF abnormally expressed tumor cells, have a high affinity and a low immunogenicity, and have a significant anti-tumor effect in vivo and in vitro.
Resumen de: US20260022367A1
Disclosed herein are improved broad-spectrum nanozymes for targeting RNA. The disclosed nanozymes are synthesized using recombinant ribonuclease with site-specific cysteine-substituted mutations that can be covalently functionalized with a length-tunable multithiol tether and then loaded onto gold particles through multiple gold-sulfur bonds, or inorganic particles with specific multiple ligand-to-particle-surface bonds. The disclosed nanozymes are also densely loaded with protective DNA oligonucleotides. In some embodiments, the disclosed nanozyme are core-free hollow forms. The removal of the inorganic nanoparticle cores from nanozymes can effectively eliminate the potential long-term toxicity induced by the core, and also creates a cavity for loading and delivery of small molecule drugs.
Resumen de: US20260021055A1
The present invention provides, in part, asymmetric piperazine-based lipid compounds of Formula (I′), and sub-formulas thereof or a pharmaceutically acceptable salt thereof. The compounds provided herein can be useful for delivery and expression of mRNA and encoded protein, e.g., as a component of liposomal delivery vehicle, and accordingly can be useful for treating various diseases, disorders and conditions, such as those associated with deficiency of one or more proteins.
Resumen de: US20260021046A1
The present invention relates to lipid nanoparticles capable of delivering a target substance to hepatic stellate cells. The lipid nanoparticles are for delivering a target substance to hepatic stellate cells and comprise a pH-sensitive cationic lipid including a hydrophilic portion and two hydrophobic portions, wherein an acid dissociation constant pKa of a lipid membrane constituting the lipid nanoparticles is greater than or equal to 6.7 and less than 8.2.
Resumen de: US20260021054A1
Provided herein are methods and compositions for treating parasitic diseases using nanobubbles in combination with at least one anti-parasitic agent.
Resumen de: US20260022141A1
The present application relates to epitope-targeted SIV and HIV vaccines. The invention provides novel envelope glycoproteins which may be utilized as HIV-1 vaccine immunogens, antigens for crystallization, and for identification of broadly neutralizing antibodies. The invention encompasses preparation and purification of immunogenic compositions which are formulated into vaccines of the present invention.
Resumen de: US20260021197A1
Nanoparticles suitable for delivery of a cargo to a chondrocyte, and targeting peptides comprising a chondrocyte targeting sequence, are provided. Further provided are uses of the nanoparticles and targeting peptides, for example, in treating a joint or cartilage disease or disorder.
Resumen de: US20260021199A1
The present disclosure relates to RNA nanoparticles (LNPs) for delivery of RNA to target tissues after administration, in particular after parenteral administration such as intravenous, intramuscular, subcutaneous, intratumoral, intraarterial, intradermal, dermal, intranasal, rectal or oral administration, and compositions comprising such RNA LNPs. The RNA LNPs in some embodiments comprise single-stranded RNA such as mRNA which encodes a peptide or protein of interest, such as a pharmaceutically active peptide or protein. The RNA is taken up by cells of a target tissue and the RNA is translated into the encoded peptide or protein, which may exhibit its physiological activity. Furthermore, the present disclosure relates to certain conjugates of (a) a polyoxazoline (POX) and/or polyoxazine (POZ) polymer and (b) one or more hydrophobic chains, compositions comprising such conjugates, and the uses of such conjugates and compositions.
Nº publicación: US20260021157A1 22/01/2026
Solicitante:
EXOTROPIN LLC [US]
Exotropin LLC
Resumen de: US20260021157A1
The present disclosure provides a composition containing a purified population of plant-derived exosome-like nanoparticles isolated from tissue of a vascular plant, wherein the exosome-like nanoparticles comprise a tuned cargo comprising a protein signature and an miRNA signature, wherein the tuned cargo of the plant-derived exosome-like nanoparticles is a result of exposure of the plant to combinations of abiotic stress conditions that cause the plant to modulate its signaling pathways and metabolism to ensure its survival in a challenging environment. The tuned cargo of the plant-derived exosome-like nanoparticles can modulate bioactivities of mammalian cells directly or indirectly. The present disclosure also provides a method for improving appearance of human skin and human hair health, including eyelashes and eyebrows, comprising applying a composition comprising the abiotically stressed plant-derived exosome-like nanoparticles containing the tuned cargo and a carrier; and applying the composition topically.
BOPI
Sede Electrónica
